Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42556   clinical trials with a EudraCT protocol, of which   7007   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-002100-39
    Sponsor's Protocol Code Number:PTC743-MIT-001-EP
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:
    Date on which this record was first entered in the EudraCT database:2021-02-25
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2020-002100-39
    A.3Full title of the trial
    Efficacy and Safety Study of Vatiquinone for the Treatment of Mitochondrial Disease Subjects With Refractory Epilepsy (MIT-E)
    Étude évaluant l’efficacité et la sécurité d’emploi de la vatiquinone pour le traitement de patients atteints d’une maladie mitochondriale avec épilepsie réfractaire (MIT-E)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy
    Étude évaluant l’efficacité et la sécurité d’emploi de la vatiquinone pour le traitement de patients atteints d’une maladie mitochondriale avec épilepsie réfractaire
    A.3.2Name or abbreviated title of the trial where available
    MIT-E
    A.4.1Sponsor's protocol code numberPTC743-MIT-001-EP
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04378075
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPTC THERAPEUTICS, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportPTC THERAPEUTICS, INC.
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPTC THERAPEUTICS, INC.
    B.5.2Functional name of contact pointPatient Advocacy
    B.5.3 Address:
    B.5.3.1Street Address100 CORPORATE COURT
    B.5.3.2Town/ citySOUTH PLAINFIELD
    B.5.3.3Post codeNJ 07080
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1 866-282-5873
    B.5.6E-mailmedinfo@ptcbio.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVatiquinone
    D.3.2Product code PTC743
    D.3.4Pharmaceutical form Oral solution
    D.3.4.1Specific paediatric formulation Yes
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVATIQUINONE
    D.3.9.1CAS number 1213269-98-7
    D.3.9.2Current sponsor codePTC743
    D.3.9.3Other descriptive nameEPI743; alpha-tocotrienol quinone
    D.3.9.4EV Substance CodeSUB188275
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboOral solution
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Genetically determined mitochondrial disease and associated refractory epilepsy
    Maladie mitochondriale génétiquement définie et épilepsie réfractaire associée
    E.1.1.1Medical condition in easily understood language
    Mitochondrial disease associated with refractory epilepsy
    Maladie mitochondriale associée à une épilepsie réfractaire
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10077953
    E.1.2Term Refractory epilepsy
    E.1.2System Organ Class 100000004852
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level HLT
    E.1.2Classification code 10052637
    E.1.2Term Genetic mitochondrial abnormalities NEC
    E.1.2System Organ Class 100000004850
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the effect of vatiquinone (PTC743) on reduction in observable motor seizure frequency in subjects with genetically confirmed mitochondrial disease, as assessed by a seizure diary.
    L’objectif principal de l’étude est de démontrer l’effet de la vatiquinone (PTC743) sur la réduction
    de la fréquence des crises motrices observables chez des patients atteints d’une maladie mitochondriale génétiquement confirmée, telle qu’évaluée par un journal des crises.
    E.2.2Secondary objectives of the trial
    ● To demonstrate the effects of vatiquinone on seizure-related emergency room visits and hospitalizations
    ● To demonstrate the effects of vatiquinone on occurrence of status epilepticus
    ● To demonstrate the effects of vatiquinone in monthly total seizure count
    ● To demonstrate the effects of vatiquinone in responder rate in motor and non-motor seizures
    ● To demonstrate the effects of vatiquinone on number of rescue antiepileptic medications used
    ● To demonstrate the effects of vatiquinone on health-related quality of life (using the CarerQoL-7D questionnaire)
    ● To demonstrate the effects of vatiquinone on occurrence of seizure clusters
    ● To demonstrate the safety of vatiquinone as assessed by drug-related SAEs, drug-related adverse events (AEs), and dose modifications
    ● Démontrer les effets de la vatiquinone sur les consultations aux urgences et les hospitalisations liées aux crises.
    ● Démontrer les effets de la vatiquinone sur la survenue de l’état de mal épileptique.
    ● Démontrer les effets de la vatiquinone sur le nombre total mensuel de crises.
    ● Démontrer les effets de la vatiquinone dans le taux de patients répondeurs dans les crises motrices et non motrices.
    ● Démontrer les effets de la vatiquinone sur le nombre de médicaments antiépileptiques de secours utilisés.
    ● Démontrer les effets de la vatiquinone sur la qualité de vie liée à la santé (à l’aide du questionnaire CarerQoL-7D).
    ● Démontrer les effets de la vatiquinone sur la survenue de crises répétitives.
    ● Démontrer la sécurité d’emploi de la vatiquinone, telle qu’évaluée par les EIG liés au médicament, les événements indésirables (EI) liés au médicament et les modifications de dose.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    •Signed informed consent form.
    •Genetic confirmation of inherited mitochondrial disease (secondary to either nuclear or mitochondrial DNA mutation) with associated epilepsy phenotype

    •Despite ongoing treatment with at least 2 antiepileptic drugs:
    ◦have ≥6 observed motor seizures occurring during the 28 days prior to the baseline visit (Day 0).
    ◦have ≥2 observed motor seizures in the first 14 days and ≥2 in the second 14 days of the Run-in period (Day -14).
    ◦do not have a consecutive 20-day seizure free period.
    ◦have at least 80% of seizure diary data.
    No changes to the AED regimen will be allowed during the first 24-week period.

    •Documented medical history of epilepsy symptoms associated with mitochondrial disease for at least 6 months prior to screening.
    •Consent to abstain from non-approved therapies for 30 days prior to the baseline visit (Day 0) and for the duration of the study.
    •Stable dose regimen of antiepileptic therapies 30 days prior to the baseline visit (Day 0).
    •Stable regimen of dietary supplements 30 days prior and, if on a ketogenic diet, stable ketogenic diet 90 days prior to the baseline visit (Day 0) and for duration of the study.
    •Electroencephalogram (EEG) at screening or historical EEG (taken within the last 30 days) for diagnostic confirmation of epilepsy.
    • Consentement éclairé signé
    • Confirmation génétique d’une maladie mitochondriale héréditaire (secondaire à une mutation nucléaire ou mitochondriale de l’ADN) avec phénotype d’épilepsie associé

    • Malgré un traitement en cours avec au moins 2 MAE :
    ○ Présentent ≥ 6 crises motrices observées au cours des 28 jours précédant la visite de référence
    ○ Présentent ≥ 2 crises motrices observées au cours des 14 premiers jours et ≥ 2 au cours des 14 jours suivants de la période de pré-inclusion
    ○ N’ont pas de période sans crise de 20 jours consécutifs
    ○ Ont au moins 80 % des données dans le journal des crises
    Aucune modification du schéma posologique du MAE ne sera autorisée pendant la première période de 24 semaines.

    • Antécédents médicaux documentés d’épilepsie associée à une maladie mitochondriale depuis au moins 6 mois avant la sélection
    • Consentement à s’abstenir de suivre des thérapies non approuvées pendant 30 jours avant la visite de référence et pendant toute la durée de l’étude
    • Schéma posologique stable de thérapies antiépileptiques 30 jours avant la visite de référence
    • Régime stable de compléments alimentaires 30 jours avant et, si régime cétogène, régime cétogène stable 90 jours avant la visite de référence et pendant toute la durée de l’étude
    • Électroencéphalogramme (EEG) à la sélection ou antécédent d’EEG pour la confirmation diagnostique de l’épilepsie
    E.4Principal exclusion criteria
    •Allergy to vatiquinone or sesame oil.
    •Aspartate transaminase (AST) or alanine transaminase (ALT) ≥2 × upper level of normal (ULN) at time of screening.
    •International normalized ratio (INR) ≥1.5 × ULN at time of screening.
    •Serum creatinine ≥1.5 × ULN at time of screening.
    •Participation in another interventional clinical trial 60 days prior to randomization or for the duration of this clinical trial
    •Previously received vatiquinone.
    •Concomitant treatment with drug(s) that have not received regulatory agency approval for the treatment of mitochondrial diseases.
    •Ongoing treatment with cytochrome P450 (CYP) inhibitors such as itraconazole or CYP inducers such as rifampin. Treatment with these agents must be completed at least 4 weeks prior to enrollment.
    •Pregnant or lactating participants or those sexually active participants who are unwilling to comply with proper birth control methods. Females of childbearing potential must have a negative pregnancy test at screening and during the baseline visit (Day 0).
    •Allergie à la vatiquinone ou à l’huile de sésame
    •Taux d’aspartate aminotransférase (ASAT) ou d’alanine aminotransférase (ALAT) ≥ 2 × limite supérieure de la normale (LSN) au moment de la sélection
    •INR ≥ 1,5 × LSN au moment de la sélection
    •Créatinine sérique ≥ 1,5 × LSN au moment de la sélection
    •Participation à un autre essai clinique interventionnel 60 jours avant la randomisation ou pendant la durée de cet essai clinique
    •A déjà reçu de la vatiquinone
    •Traitement concomitant par médicament(s) n’ayant pas reçu l’approbation de l’agence réglementaire pour le traitement des maladies mitochondriales
    •Traitement concomitant par idébénone
    •Traitement en cours par des inhibiteurs du cytochrome P450 (CYP) tels que l’itraconazole ou des inducteurs du CYP tels que la rifampicine. Le traitement par ces agents doit être terminé au moins 4 semaines avant l’inclusion.
    •Les patientes enceintes ou qui allaitent ou les patientes sexuellement actives qui ne souhaitent pas se conformer aux méthodes de contraception appropriées. Les femmes en âge de procréer doivent présenter un test de grossesse négatif à la sélection et lors de la visite de référence.
    E.5 End points
    E.5.1Primary end point(s)
    Percent change from Baseline to Week 24 in the Number of Observable Motor Seizures per 28 Days during the placebo-controlled phase
    Le pourcentage de variation par rapport à la référence jusqu'à semaine 24 , de la fréquence des crises motrices observables par période de 28 jours pendant la phase contrôlée par placebo
    E.5.1.1Timepoint(s) of evaluation of this end point
    Day 0, Week 24
    Jour 0, semaine 24
    E.5.2Secondary end point(s)
    1.Number of Disease-Related Hospital Days
    2.Number of Participants with Occurrences or Recurrence of Status Epilepticus
    3.Number of Participants with Disease-Related In-Patient Hospitalizations or Emergency Room Visits
    4.Number of Disease-Related In-Patient Hospital Admissions or Emergency Room Visits
    5.Change from Baseline to Week 72 in Total Seizure Frequency (All Types) per 28 Days
    6.Percentage of Participants with ≥25%, ≥50%, ≥75%, and 100% Reduction in Motor Seizures
    7.Percentage of Participants with ≥25%, ≥50%, ≥75%, and 100% Reduction in Total Seizures (All Types)
    8.Number of Participants Who Require Rescue Seizure Medication
    9.Health-Related Quality of Life as Measured by the Care-Related Quality of Life of Informal Caregivers (CarerQoL-7D) Questionnaire
    10.Number of Participants with Seizure Clusters
    1.Nombre de jours d’hospitalisation liés à la maladie
    2.Survenue ou récurrence d’un état de mal épileptique
    3.Nombre et pourcentage de patients ayant effectué une hospitalisation/des visites aux urgences liées à leur maladie
    4.Nombre d’hospitalisations/de visites aux urgences liées à la maladie des patients
    5.Variation en pourcentage par rapport à la référence jusqu'à semaine 72 de la fréquence totale des crises par période de 28 jours de tous les types
    6. Proportion de patients présentant une réduction de ≥ 25 %, ≥ 50 %, ≥ 75 % et 100 % des crises motrices
    7.Proportion de patients présentant une réduction de ≥ 25 %, ≥ 50 %, ≥ 75 % et 100 % des crises totales
    8.Nombre de médicaments de secours contre les crises
    9.Qualité de vie liée à la santé telle que mesurée par le questionnaire CarerQoL-7D
    10.Nombre de crises répétitives définies par les entrées « trop nombreuses à compter » dans les journaux des crises
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Week 24 and up to Week 72
    2. Week 24 and up to Week 72
    3. Week 24 and up to Week 72
    4. Week 24 and up to Week 72
    5. Day 0, Week 24, Week 72
    6. Week 24 and up to Week 72
    7. Week 24 and up to Week 72
    8. Week 24 and up to Week 72
    9. Week 24 and up to Week 72
    10. Week 24 and up to Week 72
    1. Semaine 24 et jusqu'à semaine 72
    2. Semaine 24 et jusqu'à semaine 72
    3. Semaine 24 et jusqu'à semaine 72
    4. Semaine 24 et jusqu'à semaine 72
    5. Jour 0, semaine 24, semaine 72
    6. Semaine 24 et jusqu'à semaine 72
    7. Semaine 24 et jusqu'à semaine 72
    8. Semaine 24 et jusqu'à semaine 72
    9.Semaine 24 et jusqu'à semaine 72
    10.Semaine 24 et jusqu'à semaine 72
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA10
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    France
    Germany
    Italy
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months7
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 80
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 40
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 40
    F.1.2Adults (18-64 years) No
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state12
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 25
    F.4.2.2In the whole clinical trial 80
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-04-30
    N.Ethics Committee Opinion of the trial application
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion
    P. End of Trial
    P.End of Trial Status
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA